{{medical}}
{{Infobox medical condition
| Name = 胰神經內分泌腫瘤
| Image = Diagram showing the position of the pancreas CRUK 356.svg
| Caption = 圖中黃色的臟器即為胰臟
| field = [[肿瘤学|肿瘤学]]
| DiseasesDB = 
| ICD10 = C25.4
| ICD9 = 
| ICDO = 
| OMIM = 
| MedlinePlus = 
| eMedicineSubj = 
| eMedicineTopic = 
| MeshID = 
| Synonyms = 胰島細胞瘤（islet cell tumors）<ref name="Burns2012"/><ref name="PDQ"/>，或胰內分泌細胞瘤（pancreaticdocrine tumors）<ref name="Klimstra2010"/><ref>{{Cite journal | pmid = 21167379| year = 2010| author1 = Oberg| first1 = K| title = Pancreatic endocrine tumors| journal = Seminars in Oncology| volume = 37| issue = 6| pages = 594–618| doi = 10.1053/j.seminoncol.2010.10.014}}</ref>
}}

'''胰神經內分泌瘤'''（Pancreatic neuroendocrine tumors，簡稱'''PanNETs'''、'''PETs'''，或'''PNETs'''），是源自於[[胰臟|胰臟]][[神经分泌细胞|神经分泌细胞]]的[[腫瘤|腫瘤]]。PanNETs屬於一種[[神經內分泌腫瘤|神經內分泌腫瘤]]，可能為{{tsl|en|malignant|惡性}}或[[良性|良性]]，占[[神經內分泌腫瘤|胃腸胰神經內分泌腫瘤]]（GEP-NETs）的1/3。

PanNETs並不常見，僅占所有胰臟腫瘤的 1 至 2% 。

==分類==
PanNET可以根據功能性，與腫瘤分級和分期來進行分類：

=== 功能性分類 ===
功能型（functional）和非功能型（nonfunctional）兩大類，功能型PanNETs的腫瘤會過度分泌[[激素|激素]]，造成患者產生相對應的症狀，反之則為非功能型<ref name=":0" />。功能型約占所有PanNETs的 10-60 % ，通常會較非功能型早期診斷，且幾乎皆為良性<ref name=":0" />。
{| class="wikitable"
|+PNET的功能性分類<ref>{{Cite book|url=https://www.ncbi.nlm.nih.gov/books/NBK279074/|title=Endotext|last=Vinik|first=Aaron|last2=Casellini|first2=Carolina|last3=Perry|first3=Roger R.|last4=Feliberti|first4=Eric|last5=Vingan|first5=Harlan|date=2015|publisher=MDText.com, Inc.|year=|isbn=|editor-last=De Groot|editor-first=Leslie J.|location=South Dartmouth (MA)|pages=|pmid=25905300|editor-last2=Chrousos|editor-first2=George|editor-last3=Dungan|editor-first3=Kathleen|editor-last4=Feingold|editor-first4=Kenneth R.|editor-last5=Grossman|editor-first5=Ashley|editor-last6=Hershman|editor-first6=Jerome M.|editor-last7=Koch|editor-first7=Christian|editor-last8=Korbonits|editor-first8=Márta|editor-last9=McLachlan|editor-first9=Robert}}</ref><ref name=":0">{{Cite journal|title=Pancreatic neuroendocrine tumors|url=https://www.jstage.jst.go.jp/article/irdr/6/1/6_2017.01007/_article/-char/ja/|last=Sun|first=Jian|date=2017|journal=Intractable & Rare Diseases Research|issue=1|doi=10.5582/irdr.2017.01007|volume=6|pages=21–28|language=en|issn=2186-361X}}</ref>
!類型
!腫瘤原發位置
!生物標記
!症狀
!備註
|-
|[[胰島素瘤|胰島素瘤]]（Insulinoma）
|胰臟頭部、體部，及尾部
|胰島素、{{tsl|en|proinsulin|胰島素原|}}、[[C-胜肽|C-胜肽]]（C-peptide）
|低血糖、{{Le|惠普三要項|Whipple triad}}（Whipple triad）
|最常見的PanNETs
|-
|[[胃泌素瘤|胃泌素瘤]]（Gastrinoma） 
|胃泌素瘤三角（Gastrinoma triangle）
|[[胃泌素|胃泌素瘤]]、 胰多肽（polypeptide，PP）
|{{Le|Zollinger–Ellison症候群|Zollinger–Ellison syndrome}}（胃潰瘍、上腹痛、腹瀉）
|次常見
|-
|{{tsl|en|VIPoma|血管活性腸肽瘤|}}（VIPoma） 
|胰臟體部，及尾部
|血管活性腸肽（VIP）
|Verner-Morrison症候群（水瀉、低血鉀、脫水、{{Le|胃酸缺乏|achlorhydria}}）
|罕見
|-
|升糖素瘤（Glucagonoma）
|胰臟體部，及尾部
|[[胰高血糖素|升糖素]]、腸升糖素（glycentin）
|紅疹、{{Le|遊走性紅斑|Necrolytic migratory erythema}}、[[糖尿病|糖尿病]]、[[惡病體質|惡病質]]
|罕見
|-
|{{tsl|en|Somatostatinoma|體制素瘤|}}（Somatostatinoma）
| colspan="1" rowspan="1" |胰十二指腸溝（Pancreatoduodenal groove）、壺腹、壺腹周圍
|[[體抑素|體抑素]]
|糖尿病、[[膽石病|膽石病]]、腹瀉
|罕見
|-
|[[胰多肽瘤|胰多肽瘤]]（PPoma）
|胰臟頭部
|{{tsl|en|pancreatic polypeptide|胰多肽}}
|
|罕見
|-
|[[促腎上腺皮質激素瘤|促腎上腺皮質素瘤]]（ACTHoma）
|胰臟
|[[促腎上腺皮質激素|促腎上腺皮質激素]]（ACTH）
|[[庫興氏症候群|庫欣氏症候群]]
|罕見，發生於胰臟者占異位性庫欣氏症的4-16%
|-
|[[類癌|類癌]]
|胰臟
|[[血清素|血清素]]
|潮紅、腹瀉
|罕見，發生於胰臟者占所有類癌症後群的1%
|-
|副甲狀腺荷爾蒙相關蛋白瘤（PTHrp-oma）
|胰臟
|副甲狀腺荷爾蒙相關蛋白（PTHrp）
|高血鈣症狀，症狀會類似副甲狀腺過高
|罕見
|}

=== 腫瘤分級 ===
2017年世界衛生組織（WHO）分類系統將 PanNETs 分為三級。該分類系統相對於過去的分類，更強調[[腫瘤分級|腫瘤的分級]]<ref>{{Cite journal|title=The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems|author=|url=http://www.seen.es/docs/apartados/470/The_Pathologic_Classification_of_Neuroendocrine.2.pdf|last=Klimstra|first=David S.|last2=Modlin|first2=Irvin R.|date=August 2010|journal=Pancreas|issue=6|doi=10.1097/MPA.0b013e3181ec124e|others=|year=|volume=39|page=|pages=707–712|issn=1536-4828|pmid=20664470|last3=Coppola|first3=Domenico|last4=Lloyd|first4=Ricardo V.|last5=Suster|first5=Saul}}</ref>。
{| class="wikitable"
|+'''2017年WHO胰臟神經內分泌腫瘤（PanNETs）分類系統'''<ref>{{Cite journal|title=Classification des tumeurs neuroendocrines pancréatiques : nouveautés introduites par la classification OMS 2017 des tumeurs des organes endocrines et perspectives|url=https://europepmc.org/abstract/med/29169836|last=Scoazec|first=Jean-Yves|last2=Couvelard|first2=Anne|date=2017-12|journal=Annales de Pathologie|issue=6|doi=10.1016/j.annpat.2017.10.003|volume=37|pages=444–456|language=en|issn=0242-6498}}</ref>
!分類/分級
!Ki-67增殖指數*（%）
!有絲分裂指數（%）
|-
| colspan="3" |'''分化良好的PanNETs'''
|-
|PanNET G1
|<3
|<2
|-
|PanNET G2
|3 to 20
|2 to 20
|-
|PanNET G3
|>20
|>20
|-
| colspan="3" |'''分化不好的PanNETs：胰臟神經內分泌癌（Pancreatic neuroendocrine carcinomas，PanNECs）'''
|-
|PanNEC (G3)
|>20
|>20
|-
|小細胞型（Small cell type）
|
|
|-
|大細胞型（Large cell type）
|
|
|-
| colspan="3" |'''混合型'''：腫瘤同時由神經內分泌細胞及非神經內分泌細胞構成
|}

=== 腫瘤分期 ===
目前關於PanNETs分類系統主要有歐洲內分泌腫瘤協會（ENETS）系統<ref name="Oberg-2012" />，以及AJCC系統兩種，兩者皆使用TNM系統進行分期<ref name=":0" />。

==症狀及徵象==
功能型PanNETs的症狀大多與其分泌激素相關，主要症狀源自於該激素過量的表現<ref name=":1" />。非功能型雖也會分泌多種激素，但其激素過量症狀並不若功能型那樣明顯。非功能型PanNETs主要的症狀源自於壓迫周圍器官或是[[遠端轉移|遠端轉移]]的症狀<ref>{{Cite journal|title=Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005|author=|url=https://www.ncbi.nlm.nih.gov/pubmed/17438169|last=Vagefi|first=Parsia A.|last2=Razo|first2=Oswaldo|date=2007-4|journal=Archives of Surgery (Chicago, Ill.: 1960)|issue=4|doi=10.1001/archsurg.142.4.347|others=|year=|volume=142|page=|pages=347–354|issn=0004-0010|pmc=3979851|pmid=17438169|last3=Deshpande|first3=Vikram|last4=McGrath|first4=Deborah J.|last5=Lauwers|first5=Gregory Y.|last6=Thayer|first6=Sarah P.|last7=Warshaw|first7=Andrew L.|last8=Fernández-Del Castillo|first8=Carlos}}</ref><ref>{{Cite journal|title=Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors|url=https://www.ncbi.nlm.nih.gov/pubmed/20623205|last=Li|first=Ji|last2=Luo|first2=Guopei|date=2011-12|journal=Medical Oncology (Northwood, London, England)|issue=4|doi=10.1007/s12032-010-9611-3|volume=28|pages=1027–1031|issn=1559-131X|pmid=20623205|last3=Fu|first3=Deliang|last4=Jin|first4=Chen|last5=Hao|first5=Sijie|last6=Yang|first6=Feng|last7=Wang|first7=Xiaoyi|last8=Yao|first8=Lie|last9=Ni|first9=Quanxing}}</ref><ref>{{Cite journal|title=Nonfunctioning neuroendocrine pancreatic tumors: our experience and management|url=https://www.ncbi.nlm.nih.gov/pubmed/19365596|last=Nomura|first=Naohiro|last2=Fujii|first2=Tsutomu|date=2009|journal=Journal of Hepato-Biliary-Pancreatic Surgery|issue=5|doi=10.1007/s00534-009-0099-1|volume=16|pages=639–647|issn=1436-0691|pmid=19365596|last3=Kanazumi|first3=Naohito|last4=Takeda|first4=Shin|last5=Nomoto|first5=Shuji|last6=Kasuya|first6=Hideki|last7=Sugimoto|first7=Hiroyuki|last8=Yamada|first8=Suguru|last9=Nakao|first9=Akimasa}}</ref>。但隨著影像學的進步，非功能型PanNETs有時會在壓迫症狀出現之前，就意外診斷出來<ref name="NCCN_NET201501" />{{rp|43–44}}。有時時非功能型的PanNETs也會在疾病後期出現激素過量症狀<ref>{{Cite journal|title=Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study|url=https://www.ncbi.nlm.nih.gov/pubmed/25984844|last=de Mestier|first=Louis|last2=Hentic|first2=Olivia|date=2015-05-19|journal=Annals of Internal Medicine|issue=10|doi=10.7326/M14-2132|volume=162|pages=682–689|issn=1539-3704|pmid=25984844|last3=Cros|first3=Jérôme|last4=Walter|first4=Thomas|last5=Roquin|first5=Guillaume|last6=Brixi|first6=Hedia|last7=Lombard-Bohas|first7=Catherine|last8=Hammel|first8=Pascal|last9=Diebold|first9=Marie-Danièle}}</ref>。

== 命名 ==
PanNETs過去又常被稱為胰島細胞瘤（islet cell tumors），但該名稱無法準確描述源自於胰島之外的PanNETs，因此使用該名稱者已逐漸減少<ref name=":1">{{Cite web|url=https://www.uptodate.com/contents/classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms?search=Pancreatic%20neuroendocrine%20tumors&source=search_result&selectedTitle=1~117&usage_type=default&display_rank=1#H12145093|title=Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms|accessdate=2018-05-17|author=|date=|work=www.uptodate.com|publisher=UpToDate}}</ref>。

==參見==
*[[胰臟癌|胰臟癌]]
*[[神經內分泌腫瘤|神經內分泌腫瘤]]

==參考文獻==

{{Reflist|30em|refs=

<--This reference list is organized alphanumerically by arbitrary ref name-->

<ref name="ASCOPost20110515Evero">Everolimus Approved for Pancreatic Neuroendocrine Tumors. The ASCO Post.  May 15, 2011, Volume 2, Issue 8 {{cite web |url=http://ascopost.com/articles/may-15-2011/everolimus-approved-for-pancreatic-neuroendocrine-tumors/ |title=Archived copy |accessdate=2014-12-25 |deadurl=yes |archiveurl=https://archive.is/20130117065720/http://ascopost.com/articles/may-15-2011/everolimus-approved-for-pancreatic-neuroendocrine-tumors/ |archivedate=2013-01-17 |df= }}</ref>

<ref name="Benson2010">Benson AB, Myerson RJ, and Sasson AR. Pancreatic, neuroendocrine GI, and adrenal cancers. Cancer Management: A Multidisciplinary Approach 13th edition 2010. {{ISBN|978-0-615-41824-7}} Text is available electronically (but may require free registration) at http://www.cancernetwork.com/cancer-management/pancreatic/article/10165/1802606</ref>

<ref name="Burns2012">{{cite journal|vauthors=Burns WR, Edil BH | title=Neuroendocrine pancreatic tumors: guidelines for management and update| journal=Current treatment options in oncology| date=March 2012 |volume=13| issue=1| pages=24–34| pmid=22198808| doi=10.1007/s11864-011-0172-2}}</ref>

<ref name="EU2010">{{cite news|url=http://www.genengnews.com/gen-news-highlights/pfizer-scores-new-approval-for-sutent-in-europe/81244326/ |title=Pfizer Scores New Approval for Sutent in Europe |date=2 Dec 2010 }}</ref>

<ref name="Grant2005">{{cite journal| author=Grant C  | title=Insulinoma| journal= Best Practice & Research Clinical Gastroenterology | date=2005|volume=19 | issue=5| pages=783–798 | pmid=16253900| doi=10.1016/j.bpg.2005.05.008}}</ref>

<ref name="Heaphy2011">{{cite journal |vauthors=Heaphy CM, De Wilde RF, Jiao Y, etal | date=2011| title=Altered Telomeres in Tumors with ATRX and DAXX Mutations| journal=Science |volume=333| issue=6041| pages= 425| doi=10.1126/science.1207313 | pmc=3174141 | pmid=21719641}}</ref>

<ref name="Jensen2008">{{cite journal|vauthors=Jensen RT, Berna MJ, Bingham DB, Norton JA | title=Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies| journal= Cancer | date=2008|volume=113| issue=7 Suppl| pages= 1807–1843| pmid=18798544|pmc=2574000| doi=10.1002/cncr.23648}}</ref>

<ref name="Klimstra2010">The PanNET denomination is in line with current [[世界卫生组织|WHO]] guidelines. Historically, PanNETs have also been referred to by a variety of terms, and are still often called "islet cell tumors" or "pancreatic endocrine tumors". See: {{cite journal  |vauthors=Klimstra DS, Modlin IR, Coppola D, etal |title=The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems |journal=Pancreas |volume=39 |issue=6 |pages=707–12 | date=August  2010 |pmid=20664470 |doi=10.1097/MPA.0b013e3181ec124e |url=http://www.seen.es/docs/apartados/470/The_Pathologic_Classification_of_Neuroendocrine.2.pdf}}</ref>

<ref name="NCCN_NET201501">{{cite web|title=Neuroendocrine tumors, NCCN Guidelines Version 1.2015|website=NCCN Guidelines|publisher=National Comprehensive Cancer Network, Inc.  |url=http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf|accessdate=December 25, 2014|date=November 11, 2014}}</ref>

<ref name="NCIPET">National Cancer Institute. Cancer Drug Information. FDA Approval for Sunitinib Malate. Pancreatic Neuroendocrine Tumors http://www.cancer.gov/cancertopics/druginfo/fda-sunitinib-malate</ref>

<ref name=Oberg-2012>{{cite journal |vauthors=Öberg K, Knigge U, Kwekkeboom D, Perren A |title=Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |journal=Annals of Oncology |volume=23 Suppl 7 |issue= |pages=vii124–30 | date=October  2012 |pmid=22997445 |doi=10.1093/annonc/mds295 |url=http://annonc.oxfordjournals.org/content/23/suppl_7/vii124.long#T2}} ([http://annonc.oxfordjournals.org/content/23/suppl_7/vii124/T5.expansion.html Table 5] outlines the proposed TNM staging system for PanNETs.)</ref>

<ref name="PDQ">Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ) Health Professional Version.   National Cancer Institute. March 7, 2014. [https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032521/can]</ref>

<ref name="Ramage2005">{{cite journal  |vauthors=Ramage JK, Davies AH, Ardill J, etal |title=Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours |journal=Gut |volume=Suppl 4 |issue= suppl_4|pages=iv1–16 |date=Jun 2005 |series=54 |pmid=15888809|pmc=1867801|doi=10.1136/gut.2004.053314|url=http://gut.bmj.com/cgi/content/full/54/suppl_4/iv1}}</ref>

<ref name= "Raymond2011">{{cite journal  |vauthors=Raymond E, Dahan L, Raoul JL, etal | year = 2011 | title = Sunitinib malate for the treatment of pancreatic neuroendocrine tumors | url = | journal = N Engl J Med | volume = 364 | issue = 6| pages = 501–13 | pmid = 21306237 | doi=10.1056/NEJMoa1003825}}</ref>

<ref name="Sutent-PI">http://labeling.pfizer.com/ShowLabeling.aspx?id=607</ref>

<ref name="Tejani2014">{{cite journal |vauthors=Tejani MA, Saif MW |title=Pancreatic neuroendocrine tumors: does chemotherapy work? |journal=JOP |volume=15 |issue=2 |pages=132–4 |year=2014 |pmid=24618436 |doi=10.6092/1590-8577/2301}}</ref>

}}

==外部連結==
* {{DMOZ|Health/Conditions_and_Diseases/Cancer/Gastrointestinal/Pancreatic/Neuroendocrine/}}

{{Endocrine gland neoplasia}}
{{Epithelial neoplasms}}

[[Category:胰臟癌|Category:胰臟癌]]